14 results on '"Hasan, Ali"'
Search Results
2. Liver transplantation for acute liver failure due to toxic agent ingestion in children
- Author
-
Akman, Sezin Asik, Cakir, Murat, Baran, Masallah, Arikan, Cigdem, Yuksekkaya, Hasan Ali, Tumgor, Gokhan, Saz, Ulas Eylem, Zeytunlu, Murat, Kilic, Murat, and Aydogdu, Sema
- Published
- 2009
- Full Text
- View/download PDF
3. Association of mast cells and liver allograft rejection
- Author
-
Arikan, Cigdem, Nart, Deniz, Kilic, Murat, Yuksekkaya, Hasan Ali, and Aydogdu, Sema
- Published
- 2008
4. Childhood cirrhosis, hepatopulmonary syndrome and liver transplantation
- Author
-
Tumgor, Gokhan, Arikan, Cigdem, Yuksekkaya, Hasan Ali, Cakir, Murat, Levent, Erturk, Yagci, Rasit Vural, Kilic, Murat, and Aydogdu, Sema
- Published
- 2008
5. Liver transplantation for progressive familial intrahepatic cholestasis: Clinical and histopathological findings, outcome and impact on growth
- Author
-
Aydogdu, Sema, Cakir, Murat, Arikan, C., Tumgor, Gokhan, Yuksekkaya, Hasan Ali, Yilmaz, Funda, and Kilic, Murat
- Published
- 2007
6. Successful treatment of a child having generalized Kaposi's sarcoma after living donor liver transplantation with conversion to sirolimus
- Author
-
Cigdem Arikan, Hasan Ali Yuksekkaya, Sema Aydogdu, Maşallah Baran, Ayse Yazici, and Murat Kilic
- Subjects
medicine.medical_specialty ,medicine.medical_treatment ,Liver transplantation ,Gastroenterology ,Tacrolimus ,Organ transplantation ,Immunocompromised Host ,Internal medicine ,Living Donors ,medicine ,Humans ,Sarcoma, Kaposi ,Kaposi's sarcoma ,Antibacterial agent ,Sirolimus ,Transplantation ,Antibiotics, Antineoplastic ,business.industry ,Infant ,Immunosuppression ,medicine.disease ,Liver Transplantation ,Surgery ,Treatment Outcome ,Pediatrics, Perinatology and Child Health ,Female ,Sarcoma ,business ,Immunosuppressive Agents ,medicine.drug - Abstract
SRL is a new and potent immunosuppressive agent that has been successfully introduced in organ transplantation. In contrast to other immunosuppressive agents, SRL has a potent antitumor activity both in vitro and in vivo. Herein, we report a child with Kaposi's sarcoma that was diagnosed 30 months after LDLT and treated successfully with only conversion to SRL monotherapy. KS regressed completely at the end of the first month and remained in remission during 28 months follow-up.
- Published
- 2009
7. Childhood cirrhosis, hepatopulmonary syndrome and liver transplantation
- Author
-
Murat Kilic, Sema Aydogdu, Cigdem Arikan, Ertürk Levent, Hasan Ali Yuksekkaya, Gokhan Tumgor, Murat Cakir, and Rasit Vural Yagci
- Subjects
Adult ,Liver Cirrhosis ,Male ,medicine.medical_specialty ,Cirrhosis ,Adolescent ,medicine.medical_treatment ,Liver transplantation ,Gastroenterology ,Liver disease ,Internal medicine ,medicine ,Humans ,Child ,Hepatopulmonary syndrome ,Transplantation ,business.industry ,Infant ,Hepatology ,medicine.disease ,Pulmonary hypertension ,Liver Transplantation ,Surgery ,Oxygen tension ,Treatment Outcome ,Echocardiography ,Child, Preschool ,Pediatrics, Perinatology and Child Health ,Portal hypertension ,Female ,Blood Gas Analysis ,business ,Follow-Up Studies ,Hepatopulmonary Syndrome - Abstract
Objectives: The hepatopulmonary syndrome (HPS) is characterized as a triad: liver disease, intrapulmonary vascular dilatatiton, and arterial hypoxemia. The aim of this study is to analyze outcome of children with HPS in liver transplant era. Methods: Between September 1996 and November 2006, 172 cirrhotic patients (median age 5 years; range 0.2–22 years, M/F; 97/75) were followed at Ege University Pediatric Gastroenterology, Hepatology and Nutrition Unit. All patients were evaluated by chest radiography, arterial blood gas analysis, and alveolar-arterial oxygen tension difference, contrast echocardiography (CEE) after and before the liver transplantation. Results: HPS was diagnosed in 33 patients (19%) by CEE. None of them had pulmonary hypertension. HPS was not found related to etiology of the liver disease. Portal hypertension was found related to the development of HPS (75.7% in patients with HPS and 54.6% in others, p = 0.02). 17 of 33 patients with HPS underwent liver transplantation. Preoperative and postoperative period of these patients was uneventful. Patients were extubated in the operating room except for two. Median follow up of transplanted children was 1.9 year (range; 0.75–10 years). Arterial blood gas analysis and CEE positivity regressed in all of them by postoperative 6th month. Conclusions: HPS is a serious and important complication of cirrhotic children that leads to tissue hypoxia and central cyanosis. HPS seems reversible after liver transplantation in all patients.
- Published
- 2008
8. Liver transplantation for progressive familial intrahepatic cholestasis: Clinical and histopathological findings, outcome and impact on growth
- Author
-
Funda Yilmaz, Murat Kilic, Hasan Ali Yuksekkaya, Cigdem Arikan, Murat Cakir, Sema Aydogdu, and Gokhan Tumgor
- Subjects
Transplantation ,medicine.medical_specialty ,Cirrhosis ,business.industry ,medicine.medical_treatment ,Progressive familial intrahepatic cholestasis ,Metabolic acidosis ,Liver transplantation ,Jaundice ,medicine.disease ,Short stature ,Gastroenterology ,Surgery ,Cholestasis ,Internal medicine ,Pediatrics, Perinatology and Child Health ,medicine ,medicine.symptom ,business - Abstract
In this study, we analyze the demographic features, clinical and histopathological findings in patients who underwent liver transplantation for progressive familial intrahepatic cholestasis. We also analyze outcome and impact of liver transplantation on growth and bone mineral content. Most of the patients were presented with jaundice mainly beginning within the first six months. At the time of initial admission; eight patients had short stature (height SD score
- Published
- 2007
9. An autoimmune disease refractory to immunosuppressive regimens: Celiac disease diagnosed long after liver transplantation
- Author
-
Sema Aydogdu, Çiğdem Ecevit, Hasan Ali Yuksekkaya, Miray Karakoyun, Rasit Vural Yagci, Basak Doganavsargil, and Fatih Ünal
- Subjects
Adult ,Diarrhea ,Liver Cirrhosis ,Time Factors ,Cirrhosis ,medicine.medical_treatment ,Disease ,Liver transplantation ,Autoimmune Diseases ,Diet, Gluten-Free ,Immune system ,medicine ,Humans ,Inflammation ,Autoimmune disease ,Transplantation ,business.industry ,Liver Diseases ,Endoscopy ,medicine.disease ,Liver Transplantation ,Celiac Disease ,Regimen ,Immunosuppressive drug ,Pediatrics, Perinatology and Child Health ,Immunology ,Female ,medicine.symptom ,business ,Immunosuppressive Agents - Abstract
CD is defined as T-lymphocyte-mediated gluten sensitivity. Although CD is known to affect the small intestine, it is nonetheless a multisystem disorder. Liver involvement in CD may vary from isolated hypertransaminasemia to cirrhosis. Because CD is an inappropriate immune response to gluten proteins, strict gluten-free diet is the principal therapy, along with management of liver dysfunction. In patients who fail to respond to a gluten-free diet, immunosuppressive drugs may improve intestinal inflammatory activity in untreated CD. The present case report is of a 25-yr-old woman with diarrhea lasting several weeks. The patient had received a liver transplant 13 yr earlier, and presented with cryptogenic cirrhosis diagnosed as CD. This appears to be the first case of its kind in which a pediatric long-term liver transplant patient presents with diarrhea eventually diagnosed as CD whose diet included gluten, and who was treated by an immunosuppressive drug regimen. Because of the normalization of CD-related antibodies in the post-transplantation period without gluten restriction, CD should be part of a list of diagnostic possibilities in liver transplant patients presenting with diarrhea of unknown etiology.
- Published
- 2013
10. Late-onset graft-versus-host disease after pediatric living-related liver transplantation for Langerhans cell histiocytosis
- Author
-
Hasan Ali, Yuksekkaya, Cigdem, Arikan, Gokhan, Tumgor, Serap, Aksoylar, Murat, Kilic, and Sema, Aydogdu
- Subjects
Adult ,Male ,Biopsy ,Prednisolone ,Recombinant Fusion Proteins ,Antibodies, Monoclonal ,Graft vs Host Disease ,Infant ,Liver Transplantation ,End Stage Liver Disease ,Basiliximab ,Phenotype ,Erythema ,HLA Antigens ,Langerhans Cells ,Living Donors ,Humans ,Female ,Antilymphocyte Serum ,Bone Marrow Transplantation - Abstract
GVHD is the most common and well-known cause of morbidity and mortality following allogeneic BM transplantation. The GVHD following OLT is an uncommon complication but has a high mortality and poses a major diagnostic and therapeutic challenge. We herein discussed a 12-month-old girl with multi-system LCH, who developed end-stage liver disease despite intensive chemotherapy. She underwent ABO-compatible liver transplantation at 28 months while in remission from LCH. The donor was her 26-yr-old father. Post-operative course was uneventful. The GVHD manifested with skin rash and BM suppression on post-transplant day 94 and confirmed by both microchimerism and skin biopsy. Prednisolone, basiliximab, and ATG were administered immediately but the bone marrow suppression was not improved and the patient died because of Candida sepsis at six-month post-transplant. GVHD after OLT should be keep in mind in patients with rash and BM suppression after liver transplantation. In LDLT, a patient who carries risk factors should investigated for optimal HLA matching.
- Published
- 2011
11. Late-onset graft-versus-host disease after pediatric living-related liver transplantation for Langerhans cell histiocytosis
- Author
-
Sema Aydogdu, Gokhan Tumgor, Serap Aksoylar, Cigdem Arikan, Murat Kilic, and Hasan Ali Yuksekkaya
- Subjects
Transplantation ,medicine.medical_specialty ,Basiliximab ,business.industry ,medicine.medical_treatment ,Liver transplantation ,medicine.disease ,Rash ,Surgery ,Liver disease ,surgical procedures, operative ,Graft-versus-host disease ,Langerhans cell histiocytosis ,Pediatrics, Perinatology and Child Health ,medicine ,Prednisolone ,medicine.symptom ,business ,medicine.drug - Abstract
Yuksekkaya HA, Arikan C, Tumgor G, Aksoylar S, Kilic M, Aydogdu S. Late-onset graft-versus-host disease after pediatric living-related liver transplantation for Langerhans cell histiocytosis. Pediatr Transplantation 2011: 15: E105–E109. © 2009 John Wiley & Sons A/S. Abstract: GVHD is the most common and well-known cause of morbidity and mortality following allogeneic BM transplantation. The GVHD following OLT is an uncommon complication but has a high mortality and poses a major diagnostic and therapeutic challenge. We herein discussed a 12-month-old girl with multi-system LCH, who developed end-stage liver disease despite intensive chemotherapy. She underwent ABO-compatible liver transplantation at 28 months while in remission from LCH. The donor was her 26-yr-old father. Post-operative course was uneventful. The GVHD manifested with skin rash and BM supression on post-transplant day 94 and confirmed by both microchimerism and skin biopsy. Prednisolone, basiliximab, and ATG were administered immediately but the bone marow suppression was not improved and the patient died because of Candida sepsis at six-month post-transplant. GVHD after OLT should be keep in mind in patients with rash and BM suppression after liver transplantation. In LDLT, a patient who carries risk factors should investigated for optimal HLA matching.
- Published
- 2009
12. Impact of liver transplantation on rate-corrected QT interval and myocardial function in children with chronic liver disease*
- Author
-
Ertürk Levent, Gokhan Tumgor, Hasan Ali Yuksekkaya, Murat Kilic, Cigdem Arikan, Rasit Vural Yagci, and Sema Aydogdu
- Subjects
Male ,congenital, hereditary, and neonatal diseases and abnormalities ,medicine.medical_specialty ,Adolescent ,medicine.medical_treatment ,Liver transplantation ,Chronic liver disease ,QT interval ,Electrocardiography ,Internal medicine ,Medicine ,Humans ,cardiovascular diseases ,Longitudinal Studies ,Child ,Retrospective Studies ,Transplantation ,Ejection fraction ,business.industry ,Proportional hazards model ,Liver Diseases ,Infant ,Retrospective cohort study ,Arrhythmias, Cardiac ,medicine.disease ,Surgery ,Liver Transplantation ,Child, Preschool ,Pediatrics, Perinatology and Child Health ,Chronic Disease ,cardiovascular system ,Cardiology ,Portal hypertension ,Female ,business ,circulatory and respiratory physiology - Abstract
Prolonged QTc interval (>440 ms) is a common abnormality in adult patients with CLD and has been reported to predict patient survival. In this study, 88 children who underwent evaluation for LT, including a 12-lead electrocardiogram and echocardiogram included to determine the frequency of QTc prolongation and related factors in children with CLD and the effect of LT on these factors. Sixty-nine healthy, age- and sex-matched children served as controls. QTc interval was prolonged in 40 CLD patients (45.4%). It was found to be related to PELD score and presence of portal hypertension. Mean QTc was higher in patients who died prior to LT than in the survivors without LT. Mortality risk was increased 3.66-fold in patients with prolonged QTc (p = 0.001, 95% CI: 2-7.2). Cox regression analysis showed that only PELD score was an independent predictor of survival (p = 0.001, beta = -0.41, 95% CI: 5.58-1.82). Five of 48 transplanted children died within three months post-transplant; QTc was not related to post-transplant survival (p = 0.27). QTc normalized in 63.8% patients after LT. After LT, LAD, LVEF, and LVPWT decreased. In conclusion, QTc prolongation is common in children with CLD and associated with high mortality. It may be useful for assessment of the severity of CLD and for the timing for transplantation.
- Published
- 2008
13. Association of mast cells and liver allograft rejection
- Author
-
Murat Kilic, Sema Aydogdu, Hasan Ali Yuksekkaya, Cigdem Arikan, and Deniz Nart
- Subjects
Graft Rejection ,Male ,medicine.medical_specialty ,Pathology ,Adolescent ,medicine.medical_treatment ,Biopsy ,Liver transplantation ,Gastroenterology ,Immune system ,Internal medicine ,medicine ,Humans ,Mast Cells ,Child ,Retrospective Studies ,Hepatitis ,Inflammation ,Transplantation ,medicine.diagnostic_test ,business.industry ,Graft Survival ,Infant ,medicine.disease ,Mast cell ,Liver Transplantation ,medicine.anatomical_structure ,Liver ,Allograft rejection ,Child, Preschool ,Pediatrics, Perinatology and Child Health ,Graft survival ,Histopathology ,Female ,business ,Immunosuppressive Agents - Abstract
MCs are important effector cells in a broad range of immune responses. Their role in liver allograft rejection is not clear. Twenty-one liver transplant recipients (mean age +/- s.d.; 10.2 +/- 4.1 yr) who experienced a rejection episode are included in this study. Biopsy specimens from normal livers (allograft biopsy with normal histopathology n = 5 and naive livers n = 6), transplanted livers with CR (n = 5), and transplanted livers with ACR (n = 26) were studied. The total number of PT in each biopsy specimen was documented, and the number of PT that contained MCs was expressed as a percentage of the total number of PT. MCs, percentage of PT containing MCs and the average number of MCs/PT was significantly higher in rejection specimens than in control biopsy samples. All parameters were significantly higher in CR group than AR groups. Increasing grades of rejection was also associated with progressively more MCs and MC/PT (r = 0.68 p = 0.000; r = 0.58 p = 0.002). Only serum bilirubin level was related to the MCs in AR group. Only MC/PT was detected as an independent predictor of graft survival (p = 0.011, RR 2.87 95% CI 1.3-6.5). Despite the fact that the role of MCs in liver allograft rejection is still unknown; they exist in inflammatory infiltrates during pediatric liver allograft rejection. MC-rich portal infiltrates may distinguish chronic liver rejection from other inflammatory states such as AR, hepatitis and biliary obstruction.
- Published
- 2008
14. Liver transplantation for progressive familial intrahepatic cholestasis: clinical and histopathological findings, outcome and impact on growth
- Author
-
Sema, Aydogdu, Murat, Cakir, C, Arikan, Gokhan, Tumgor, Hasan Ali, Yuksekkaya, Funda, Yilmaz, and Murat, Kilic
- Subjects
Male ,Treatment Outcome ,Bone Density ,Child, Preschool ,Disease Progression ,Humans ,Infant ,Female ,Cholestasis, Intrahepatic ,Growth ,Child ,Liver Transplantation - Abstract
In this study, we analyze the demographic features, clinical and histopathological findings in patients who underwent liver transplantation for progressive familial intrahepatic cholestasis. We also analyze outcome and impact of liver transplantation on growth and bone mineral content. Most of the patients were presented with jaundice mainly beginning within the first six months. At the time of initial admission; eight patients had short stature (height SD score2), and four patients had weight SD score2. Liver transplantation were performed at the age of 43.2+/-27 months (range 9 to 96 months), 6.5+/-3.5 months later after the first admission. Infection, surgical complications and osmotic diarrhea associated with severe metabolic acidosis were noted in 41.4%, 16.6% and 33.3%, respectively. One patient developed posttransplant lymphoproliferative disorder. Overall; 1 year graft and patient survival was 69.2% and 75%, respectively. At the end of the 1st year only 2 patients had height SD score2. Linear regression of height gain against increase in total body BMD measured at the time of transplantation and 1 year after liver transplantation gave a coefficient r=0.588 (p=0.074). No correlation was found between the height gain and age and PELD score at time of transplantation, and no difference was noted between the sexes and donor type. Liver transplantation is effective treatment modality with good outcome and little morbidity, and increases the growth acceleration in patients with PFIC associated with cirrhosis.
- Published
- 2007
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.